Michael T McHale
Overview
Explore the profile of Michael T McHale including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
620
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang Y, Ojalill M, Boyer A, Chen X, Tahon E, Thivolle Lioux G, et al.
Cancer Res Commun
. 2024 Nov;
4(12):3165-3179.
PMID: 39585085
FAK inhibitors are in combinatorial clinical testing with agents that prevent Ras-Raf-MAPK pathway activation in various cancers. This study suggests that nuclear FAK limits ERK/MAPK activation in supporting HGSOC cell...
2.
3.
Brodsky A, Hom-Tedla M, Fadare O, McHale M
Gynecol Oncol Rep
. 2022 May;
41:100994.
PMID: 35574244
We present an unusual case of a 28-year-old female who had atypical trophoblastic proliferation on her endocervical curettage (ECC) performed at the time of a colposcopy. The indication for colposcopy...
4.
Yusufaly T, Zou J, Nelson T, Williamson C, Simon A, Singhal M, et al.
J Nucl Med
. 2021 Oct;
63(7):1087-1093.
PMID: 34711618
Radiomics has been applied to predict recurrence in several disease sites, but current approaches are typically restricted to analyzing tumor features, neglecting nontumor information in the rest of the body....
5.
Williamson C, Sirak I, Xu R, Portelance L, Wei L, Tarnawski R, et al.
Int J Radiat Oncol Biol Phys
. 2021 Aug;
112(1):169-178.
PMID: 34419564
Purpose: To test effects of positron emission tomography (PET)-based bone marrow-sparing (BMS) image-guided intensity modulated radiation therapy (IG-IMRT) on efficacy and toxicity for patients with locoregionally advanced cervical cancer. Methods...
6.
Melber D, Berman Z, Jacobs M, Picel A, Conturie C, Zhang-Rutledge K, et al.
Am J Obstet Gynecol
. 2021 Jul;
225(4):442.e1-442.e10.
PMID: 34245679
Background: Multidisciplinary care of placenta accreta spectrum cases improves pregnancy outcomes, but the specific components of such a multidisciplinary collaboration varies between institutions. As experience with placenta accreta spectrum increases,...
7.
Charo L, Eskander R, Okamura R, Patel S, Nikanjam M, Lanman R, et al.
Mol Oncol
. 2020 Sep;
15(1):67-79.
PMID: 32881280
Molecular characterization of cancers is important in dictating prognostic factors and directing therapy. Next-generation sequencing of plasma circulating tumor DNA (ctDNA) offers less invasive, more convenient collection, and a more...
8.
Huh W, Brady W, Fracasso P, Dizon D, Powell M, Monk B, et al.
Gynecol Oncol
. 2020 Jul;
158(3):562-569.
PMID: 32641240
Objective: Women with persistent, recurrent, and/or metastatic cervical cancer have a poor prognosis. Even with the availability of cisplatin plus paclitaxel and bevacizumab, median overall survival (OS) is only 17.0 ...
9.
Konstantinopoulos P, Cheng S, Wahner Hendrickson A, Penson R, Schumer S, Doyle L, et al.
Lancet Oncol
. 2020 Jun;
21(7):957-968.
PMID: 32553118
Background: High-grade serous ovarian cancers show increased replication stress, rendering cells vulnerable to ATR inhibition because of near universal loss of the G1/S checkpoint (through deleterious TP53 mutations), premature S...
10.
Mell L, Xu R, Yashar C, McHale M, Einck J, Mayadev J, et al.
Int J Radiat Oncol Biol Phys
. 2020 Apr;
107(5):964-973.
PMID: 32334034
Purpose: The use of concurrent doublet chemotherapy with radiation for locoregionally advanced cervical cancer (LACC) is limited by gastrointestinal and hematologic toxicity. By reducing radiation dose to bowel and bone...